KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Assets Average (2016 - 2025)

Nektar Therapeutics (NKTR) has 15 years of Assets Average data on record, last reported at $254.4 million in Q3 2025.

  • For Q3 2025, Assets Average fell 21.87% year-over-year to $254.4 million; the TTM value through Sep 2025 reached $254.4 million, down 21.87%, while the annual FY2024 figure was $350.9 million, 36.69% down from the prior year.
  • Assets Average reached $254.4 million in Q3 2025 per NKTR's latest filing, up from $231.9 million in the prior quarter.
  • Across five years, Assets Average topped out at $1.5 billion in Q1 2021 and bottomed at $231.9 million in Q2 2025.
  • Average Assets Average over 5 years is $696.4 million, with a median of $528.0 million recorded in 2023.
  • Peak YoY movement for Assets Average: decreased 14.66% in 2021, then tumbled 44.01% in 2023.
  • A 5-year view of Assets Average shows it stood at $1.2 billion in 2021, then plummeted by 37.71% to $745.8 million in 2022, then plummeted by 43.67% to $420.1 million in 2023, then fell by 27.19% to $305.9 million in 2024, then fell by 16.82% to $254.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Assets Average were $254.4 million in Q3 2025, $231.9 million in Q2 2025, and $280.0 million in Q1 2025.